Anna-Lena Volckmar

List of Publications by Year
in descending order

40 papers	1,368 citations	430442 18 h-index	360668 35 g-index
42 all docs	42 docs citations	42 times ranked	2442 citing authors

#	Article	IF	Citations
1	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	1.5	15
2	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	1.4	24
3	KRAS / GNAS â€testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasoundâ€guided workup of suspected mucinous neoplasms of the pancreas. Genes Chromosomes and Cancer, 2021, 60, 489-497.	1.5	13
4	Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. Case Reports in Oncology, 2021, 14, 477-482.	0.3	8
5	<scp>RREB1â€MKL2</scp> fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?. Genes Chromosomes and Cancer, 2021, 60, 565-570.	1.5	10
6	Targeting rare and non-canonical driver variants in NSCLC â€“ An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	0.9	8
7	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	1.3	6
8	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 670483.	1.3	10
9	Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies. Translational Lung Cancer Research, 2021, 10, 2118-2131.	1.3	16
10	Knowledge bases and software support for variant interpretation in precision oncology. Briefings in Bioinformatics, 2021, 22, .	3.2	9
11	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	1.7	8
12	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open, 2021, 6, 100253.	2.0	17
13	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	3.6	42
14	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. Genes Chromosomes and Cancer, 2020, 59, 406-416.	1.5	10
15	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	2.3	14
16	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ¯ve metastatic prostate cancer â€“Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	0.8	12
17	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	1.7	32
18	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	0.5	69

#	Article	IF	Citations
19	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	1.7	36
20	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
21	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	2.3	24
22	Digital PCR After MALDIâ€“Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics - Clinical Applications, 2019, 13, e1800034.	0.8	19
23	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	2.3	95
24	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	2.3	85
25	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131
26	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes and Cancer, 2019, 58, 3-11.	1.5	14
27	Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes and Cancer, 2018, 57, 70-79.	1.5	19
28	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	1.5	20
29	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€”a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	1.3	152
30	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.3	21
31	Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. European Journal of Cancer, 2018, 104, 239-242.	1.3	43
32	A field guide for cancer diagnostics using cellâ€free DNA: From principles to practice and clinical applications. Genes Chromosomes and Cancer, 2018, 57, 123-139.	1.5	155
33	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 509-520.	1.4	29
34	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. Genes Chromosomes and Cancer, 2017, 56, 214-220.	1.5	8
35	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3Kâ€“AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	1.5	27
36	PARP inhibition in BRCA2-mutated prostate cancer. Annals of Oncology, 2017, 28, 189-191.	0.6	12

#	Article	IF	Citations
37	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	0.8	14
38	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget, 2017, 8, 77897-77914.	0.8	19
39	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. Diagnostic Pathology, 2016, 11, 133.	0.9	8
40	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. Genes Chromosomes and Cancer, 2016, 55, 505-521.	1.5	34